Your browser doesn't support javascript.
loading
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing, Z A; Fung, H Y J; Ranganathan, P; Mitchell, S; El-Gamal, D; Woyach, J A; Williams, K; Goettl, V M; Smith, J; Yu, X; Meng, X; Sun, Q; Cagatay, T; Lehman, A M; Lucas, D M; Baloglu, E; Shacham, S; Kauffman, M G; Byrd, J C; Chook, Y M; Garzon, R; Lapalombella, R.
Afiliação
  • Hing ZA; Medical Scientist Training Program, The Ohio State University, Columbus, OH, USA.
  • Fung HY; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Ranganathan P; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Mitchell S; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • El-Gamal D; The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
  • Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Williams K; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Goettl VM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Smith J; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Yu X; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Meng X; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Sun Q; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Cagatay T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Lehman AM; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Lucas DM; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Baloglu E; Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
  • Shacham S; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Kauffman MG; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Byrd JC; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Chook YM; Karyopharm Therapeutics Inc., Newton, MA, USA.
  • Garzon R; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
  • Lapalombella R; Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Leukemia ; 30(12): 2364-2372, 2016 12.
Article em En | MEDLINE | ID: mdl-27323910
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Citoplasmáticos e Nucleares / Neoplasias Hematológicas / Carioferinas / Antineoplásicos Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Citoplasmáticos e Nucleares / Neoplasias Hematológicas / Carioferinas / Antineoplásicos Idioma: En Ano de publicação: 2016 Tipo de documento: Article